Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

Authors

  • Mikkael A. Sekeres,

    Corresponding author
    1. Department of Hematologic Oncology and Blood Disorders, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
    2. Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
    • Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195
    Search for more papers by this author
  • Christine O'Keefe,

    1. Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
    Search for more papers by this author
  • Alan F. List,

    1. H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
    Search for more papers by this author
  • Katarina Paulic,

    1. Department of Hematologic Oncology and Blood Disorders, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
    Search for more papers by this author
  • Manuel Afable II,

    1. Department of Hematologic Oncology and Blood Disorders, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
    Search for more papers by this author
  • Ricki Englehaupt,

    1. Department of Hematologic Oncology and Blood Disorders, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
    Search for more papers by this author
  • Jaroslaw P. Maciejewski

    1. Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
    Search for more papers by this author

  • Conflict of interest: Celgene Corp - Advisory Board, honoraria.

No abstract is available for this article.

Ancillary